Tissue implants in treatment of parkinsonian syndromes in animals and implications for use of tissue implants in humans.
Kopin
I J
IJ
National Institute of Neurological Disorders, National Institutes of Health, Bethesda, Maryland 20892.
Bankiewicz
K S
KS
Plunkett
R J
RJ
Jacobowitz
D M
DM
Oldfield
E H
EH
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000313:Adrenal Medulla / Q000637:transplantation; D000818:Animals; D001479:Basal Ganglia / Q000503:physiopathology / Q000601:surgery; D016380:Brain Tissue Transplantation / Q000502:physiology*; D004298:Dopamine / Q000502:physiology; D016332:Fetal Tissue Transplantation / Q000502:physiology; D000882:Haplorhini; D006801:Humans; D009460:Neurologic Examination; D016627:Oxidopamine; D010300:Parkinson Disease / Q000503:physiopathology / Q000601:surgery*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000503:physiopathology / Q000601:surgery*; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology
D011954:Receptors, Dopamine; D016627:Oxidopamine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D004298:Dopamine